Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBRT plus sintilimab and fruquintinib for third-line MSS metastatic colorectal cancer
ChiCTR2300074637Phase 2Recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and fruquintinib in colorectal cancer (CRC), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Objective response rate. Started Aug 2023; status: recruiting.
02
Drugs
sintilimabfruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300074637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074637.